All News
Long-Term Benefit of Rituximab in Systemic Sclerosis
A small cohort trial of rituximab (RTX) in 29 systemic sclerosis patients showed significantly improved skin sclerosis and lung function after a follow-up of 96 weeks.
Read Article
Renal Involvement is Pivotal in ANCA-Associated Vasculitis
MedPage Today
Bearing in mind that renal impairment is among the worst complications of ANCA-associated vasculitis (AAV), researchers have identified four different trajectories of kidney function over time in AAV patients, with implications for personalized treatment, as well as future research.
Read Article
Recurrent Fevers; 3 Days at 103F QD Clinic - Lessons from the clinic, brought to you by RheumNow Live March 18 &19, 2023 - Dallas, TX https://t.co/pWrCVrxamD https://t.co/C6q9aVJ2gg
Links:
Dr. John Cush RheumNow ( View Tweet)
NSAIDs in Pregnancy
Dr. Jack Cush reviews the lastest journal articles, news, and FDA announcements from the past week on RheumNow. This week, the importance of IFNa, Subclinical PsA and NSAID safety during Pregnancy.
https://t.co/uCKNXV1zGF https://t.co/RbutI3PBjq
Links:
Dr. John Cush RheumNow ( View Tweet)
Serum beta-2 microglobulin (B2M) in 100 #SLE pts - strong correlations betw B2M & 24 hr urinary protein, BUN, creatinine, disease activity, & damage score (p < 0.001), & negatively correlated with GFR, C3, C4 (p < 0.001). B2M predicted lupus LN https://t.co/XujdKvjjoS https://t.co/vl8XXQDhXM
Links:
Dr. John Cush RheumNow ( View Tweet)
2017 Prevalence of Psoriatic arthritis (PsA) in Sweden estimated to be 0.34% (range 0.32-0.50% across all sensitivity analyses); lower in males & w/ higher level of education. 0.24% have seen rheumatology care- 32% on b/ts-DMARDs, 41% csDMARDs https://t.co/Jh2WUYVJR2 https://t.co/ZdFVIq2iQ0
Links:
Dr. John Cush RheumNow ( View Tweet)
ARTIS Swedish study of Cancer in RA or PSA pts (~15k pts) starting JAKi vs TNFi. With ~2 yrs F/U, the risk of Cancer (excluding NMSC) was similar betw JAKi and TNFi (HR 0.94; 0.65 to 1.38), but more incident NMSC w/ JAKi (HR 2.12; 1.15 to 3.89) at 2 yrs https://t.co/BiPWF1T0lZ https://t.co/nrmaCGBcce
Links:
Dr. John Cush RheumNow ( View Tweet)
Metanalysis of 3 RCTs & 19 observational studies, showed hematopoietic stem cell transplantation . (HSCT) significantly improved skin thickness and lung function. While HSCT had more deaths than IV CTX, HSCT had higher 2 yr survival rate https://t.co/6qvLJKjFES https://t.co/VHiha5FbUJ
Links:
Dr. John Cush RheumNow ( View Tweet)
Metanalysis shows Takayasu's arteritis pts are at higher risk of adverse pregnancy outcomes. (27 studies, 825 pregs) showed more miscarriage (16%), hypertension (37%) and pre-eclampsia (14%) in TA patients (p < 0.01) https://t.co/kyUNgcsIPD https://t.co/KA1otftKTc
Dr. John Cush RheumNow ( View Tweet)
Study of 197 AAV pts in RAVE trial (RTX vs CTX; followed by AZA) showed most serious infections (82%) occurred in 6 mos (68% Resp infx) & assoc w/ lower#s CD19+ cells. TMP/SMX prophylaxis against P. jirovecii decreased SIE rates https://t.co/oz530OkGs8 https://t.co/YFW7PD6wrW
Links:
Dr. John Cush RheumNow ( View Tweet)
Massachusetts Medical Society workforce survey (600 MDs) shows that >half have cut back patient time, 55% admitted to burnout (more in women), & 1 in 4 physicians plan to leave medicine in the next two years. https://t.co/VUd101BrEi https://t.co/Hc6UyGMW1E
Links:
Dr. John Cush RheumNow ( View Tweet)
Periodontal Mucosal Breaks Trigger RA Disease Activity
Periodontal disease (PD) is more common in RA, especially those with anti-citrullinated protein antibodies (ACPAs). RA activity has been linked to the severity of PD and mucosal inflammation.
https://t.co/Yx7fPMrB7v https://t.co/pH0XGPqGhJ
Links:
Dr. John Cush RheumNow ( View Tweet)
Drs Schett & Mackensen reported a case of refractory inflammatory myositis successfully treated with CD19 CAR T cells. 41yoM w/ +Jo-1, myositis, ILD, Raynauds, periorb edema, not responding to steroids, RTX, IVIG, tacrolimus, CTX https://t.co/DlKs3DGWNu https://t.co/M7qrcfcE2y
Links:
Dr. John Cush RheumNow ( View Tweet)
Study of 78 pt suspected of #GCA undergoing Temp. artery Bx and US. Nearly half (35) Dx w/ GCA. Both had similar sensitivities(69% and 63%, respectively), but specificity higher w/ biopsy (100% vs 79%). Compression sign had best diagnostic performance https://t.co/wzVqrHvfqM https://t.co/HRmfb6g7aF
Links:
Dr. John Cush RheumNow ( View Tweet)
Is it Lupus?
https://t.co/dsHQvyuCtC https://t.co/JBYGAWQJ7X
Links:
Dr. John Cush RheumNow ( View Tweet)
Phase 3 Trials of Baricitinib Disappoint in SL
Despite the encouraging phase II trial results of baricitinib in SLE patients, two parallel phase III trials have failed to redemonstrate the efficacy of baricitinib in active SLE.
https://t.co/SwU7ujZnsP https://t.co/IgpCTtyDNA
Links:
Dr. John Cush RheumNow ( View Tweet)
While anifrolumab targets IFN alfa in SLE, its unclear how much IFNa is needed for Rx response. A study of 40 pts shows Rx naive SLE has signif higher serum IFN activity; this is assoc w/ fever, leukopenia, ALE rash and oral ulcers & more organ damage https://t.co/nhqg0ky7RT https://t.co/kBuqvJYFYE
Links:
Dr. John Cush RheumNow ( View Tweet)
"My eye is swollen": an underrecognized mimic of IgG4-related disease
Artem Minalyan, MD, presenting his poster at RWCS 2023.
https://t.co/N2VShY5OHY https://t.co/fQYbFH6Mnb
Links:
Dr. John Cush RheumNow ( View Tweet)
Treat-to-Target Guidelines for GCA and PMR
The Annals of Rheumatic Disease has published updated multinational, T2T recommendations for the treatment of giant cell arteritis (GCA) and polymyalgia rheumatica (PMR).
https://t.co/zb0PXsW5mw https://t.co/PdFd9A794O
Links:
Dr. John Cush RheumNow ( View Tweet)
FDA has approved sarilumab (Kevzara) for the treatment of polymyalgia rheumatica (PMR) in adult patients who have had an inadequate response to corticosteroids or who cannot tolerate corticosteroid taper. Approval is based on Phase 3 SAPHYR study https://t.co/7GHG2uG9yQ https://t.co/MZ7RYGdDfG
Links:
Dr. John Cush RheumNow ( View Tweet)
